<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565120</url>
  </required_header>
  <id_info>
    <org_study_id>ATR-NSCLC</org_study_id>
    <nct_id>NCT03565120</nct_id>
  </id_info>
  <brief_title>Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer</brief_title>
  <official_title>The Efficacy and Toxicity of Aggressive Thoracic Radiotherapy for Stage Ⅳ Non-Small Cell Lung Cancer Patients With Controlled Extrathoracic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>yu gengsheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangmen Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the safety and efficacy of aggressive thoracic radiotherapy in
      treating patients with non-small cell lung cancer that has not progressed after the first
      line systemic therapy. In this trial, patients with stage Ⅳ non small cell lung cancer who
      did not progress after first line systemic therapy will receive the aggressive thoracic
      radiotherapy, and the safety and efficacy of aggressive thoracic radiotherapy will be
      evaluated. The primary end points of the study are overall survival (OS), the secondary end
      points are local control rate, local progression free survival(LPFS), PFS, and toxicity and
      quality of life(QOL).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>two years after the beginning of first line systemic therapy</time_frame>
    <description>overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LPFS</measure>
    <time_frame>1 year after the beginning of first line systemic therapy</time_frame>
    <description>local progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year after the beginning of first line systemic therapy</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity related to the radiotherapy</measure>
    <time_frame>from the beginning of radiotherapy to the 3 month after the completion of radiotherapy</time_frame>
    <description>assess according to the National Cancer Institute-Common Terminology Criteria for Adverse Events 3.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Stage IV</condition>
  <condition>Thoracic Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Arm-R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in this arm will receive aggressive thoracic radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Aggressive Thoracic Radiotherapy</intervention_name>
    <description>The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)</description>
    <arm_group_label>Arm-R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed NSCLC

          -  stage IV disease

          -  no progression after first line systemic therapy

          -  18 to 80 years of age

          -  Karnofsky performance status(KPS) score ≥70%

          -  no contraindications to radiation therapy

          -  presumed ability to tolerate thoracic radiation therapy to a BED≥53Gy

        Exclusion Criteria:

          -  a history of thoracic surgery, radiation therapy, or more than first line chemotherapy

          -  pregnancy or lactation at the time of enrollment

          -  previous malignancy or other concomitant malignant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Gengsheng, master</last_name>
    <role>Study Director</role>
    <affiliation>jiangmen cenctral hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li chunming, master</last_name>
    <phone>(+86)07503165905</phone>
    <email>52212007@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Gengsheng, master</last_name>
    <phone>(+86)07503165915</phone>
    <email>gengsheng_yu@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangmen central hospital</name>
      <address>
        <city>Jiangmen</city>
        <state>Guangdong</state>
        <zip>529000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunming LI, master</last_name>
      <phone>+8607503165905</phone>
      <email>52212007@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Gengsheng Yu, master</last_name>
      <phone>+863165905</phone>
      <email>gengsheng_yu@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kepka L, Olszyna-Serementa M. Palliative thoracic radiotherapy for lung cancer. Expert Rev Anticancer Ther. 2010 Apr;10(4):559-69. doi: 10.1586/era.10.22. Review.</citation>
    <PMID>20397921</PMID>
  </reference>
  <reference>
    <citation>Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E. Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol. 2008 Aug 20;26(24):4001-11. doi: 10.1200/JCO.2007.15.3312. Review.</citation>
    <PMID>18711191</PMID>
  </reference>
  <reference>
    <citation>Koshy M, Malik R, Mahmood U, Rusthoven CG, Sher DJ. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer. Pract Radiat Oncol. 2015 Nov-Dec;5(6):374-82. doi: 10.1016/j.prro.2015.07.009. Epub 2015 Aug 1.</citation>
    <PMID>26412340</PMID>
  </reference>
  <reference>
    <citation>Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):19-23. doi: 10.1016/j.ijrobp.2007.12.031. Epub 2008 Feb 14.</citation>
    <PMID>18280058</PMID>
  </reference>
  <reference>
    <citation>Su SF, Hu YX, Ouyang WW, Lu B, Ma Z, Li QS, Li HQ, Geng YC. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study. BMC Cancer. 2013 Oct 12;13:474. doi: 10.1186/1471-2407-13-474.</citation>
    <PMID>24118842</PMID>
  </reference>
  <reference>
    <citation>Sheu T, Heymach JV, Swisher SG, Rao G, Weinberg JS, Mehran R, McAleer MF, Liao Z, Aloia TA, Gomez DR. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):850-7. doi: 10.1016/j.ijrobp.2014.07.012. Epub 2014 Sep 9.</citation>
    <PMID>25216859</PMID>
  </reference>
  <reference>
    <citation>Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015 Dec 31;10(12):e0145936. doi: 10.1371/journal.pone.0145936. eCollection 2015.</citation>
    <PMID>26720170</PMID>
  </reference>
  <reference>
    <citation>Wang J, Ji Z, Wang X, Liang J, Hui Z, Lv J, Zhou Z, Yin W, Wang L. Radical thoracic radiotherapy may provide favorable outcomes for stage IV non-small cell lung cancer. Thorac Cancer. 2016 Mar;7(2):182-9. doi: 10.1111/1759-7714.12305. Epub 2015 Sep 13.</citation>
    <PMID>27042220</PMID>
  </reference>
  <reference>
    <citation>Su S, Hu Y, Ouyang W, Ma Z, Li Q, Li H, Wang Y, Wang X, Li T, Li J, Chen M, Lu Y, Bai Y, He Z, Lu B. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies. BMC Cancer. 2016 Nov 21;16(1):908.</citation>
    <PMID>27871270</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>December 23, 2018</last_update_submitted>
  <last_update_submitted_qc>December 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jiangmen Central Hospital</investigator_affiliation>
    <investigator_full_name>yu gengsheng</investigator_full_name>
    <investigator_title>Vice director of Oncology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

